» Articles » PMID: 2066755

Clinical Relevance of Tumor Cell Ploidy and N-myc Gene Amplification in Childhood Neuroblastoma: a Pediatric Oncology Group Study

Overview
Journal J Clin Oncol
Specialty Oncology
Date 1991 Apr 1
PMID 2066755
Citations 130
Authors
Affiliations
Soon will be listed here.
Abstract

We assessed tumor cell DNA content (ploidy) and N-myc gene copy number as predictors of long-term disease-free survival in 298 children with neuroblastoma. Diploid tumor stem lines were identified in 101 patients (34%), clonal hyperdiploid abnormalities in 194 (65%), and hypodiploid stem lines in three (1%). In children with widely disseminated tumors at diagnosis (stage D), ploidy had a highly age-dependent influence on prognosis. Among infants (less than 12 months) treated with cyclophosphamide-doxorubicin, hyperdiploidy was closely associated with long-term disease-free survival (greater than 90% of cases), while diploidy invariably predicted early treatment failure (P less than .001). Similarly, in children 12 to 24 months of age who were treated with cisplatin-teniposide and cyclophosphamide-doxorubicin, diploidy uniformly predicted early failure, whereas half of the children with hyperdiploidy achieved long-term disease-free survival (P less than .001). There was no relationship between ploidy and treatment outcome in children older than 24 months with stage D tumors who had a very low probability of long-term disease-free survival (less than 10%). N-myc gene amplification was detected in 37 (25%) of the 147 tumors tested, with the remainder showing single-copy levels of the gene. N-myc gene amplification was more frequent in diploid than in hyperdiploid tumors (23 of 57 v 14 of 87, P = .001) and predicted a high likelihood of early treatment failure. In children younger than 2 years with disseminated neuroblastoma, tumor cell ploidy and N-myc gene copy number provide complementary prognostic information that will distinguish patients who can be cured on current regimens from those who require new treatment strategies.

Citing Articles

Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531.

Barr E, Naranjo A, Twist C, Tenney S, Schmidt M, London W Pediatr Blood Cancer. 2024; 71(8):e31089.

PMID: 38822537 PMC: 11318088. DOI: 10.1002/pbc.31089.


Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification.

Hu X, Zhou Y, Hill C, Chen K, Cheng C, Liu X Br J Cancer. 2024; 130(11):1841-1854.

PMID: 38553589 PMC: 7616008. DOI: 10.1038/s41416-024-02666-y.


Computational completion of the Aurora interaction region of N-Myc in the Aurora a kinase complex.

Altiner P, Cinaroglu S, Timucin A, Timucin E Sci Rep. 2023; 13(1):18399.

PMID: 37884585 PMC: 10603048. DOI: 10.1038/s41598-023-45272-3.


Segmental chromosomal aberrations as the poor prognostic factor in children over 18 months with stage 3 neuroblastoma without amplification.

Wieczorek A, Szewczyk K, Klekawka T, Stefanowicz J, Ussowicz M, Drabik G Front Oncol. 2023; 13:1134772.

PMID: 36865795 PMC: 9972431. DOI: 10.3389/fonc.2023.1134772.


as a potential oncogene and a prognostic biomarker for neuroblastoma.

Song J, Ni C, Dong X, Sheng C, Qu Y, Zhu L Front Oncol. 2022; 12:988415.

PMID: 36237324 PMC: 9552328. DOI: 10.3389/fonc.2022.988415.